Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07285291
PHASE3
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Sponsor: Taisho Pharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis
Official title: A Phase 3, Randomized, Placebo-controlled, Double-blind, Phosphate Binder-combination Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-01-05
Completion Date
2026-12-29
Last Updated
2026-01-09
Healthy Volunteers
No
Interventions
DRUG
TS-172 20~60 mg/day
oral administration of TS-172 20\~60 mg/day
DRUG
Placebo
oral administration of placebo
Locations (1)
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan